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Introduction
The clinical observation that sexual dimorphism plays a
role in the immune response suggests that the endocrine
system is an important factor for the development and
maintenance of the response. There is a high frequency of
autoimmune diseases in females and an increased
immune response to antigenic stimulus. These observa-
tions make it evident that sexual dimorphism probably acts
on the immune response through its effect upon the
thymic–hypothalamic–pituitary–gonadic axis [1].
Abstract
Our goal in the present work was to determine whether male patients with untreated hypogonadism
have an increased risk of developing rheumatic/autoimmune disease (RAD), and, if so, whether there is
a relation to the type of hypogonadism. We carried out neuroendocrine, genetic, and rheumatologic
investigations in 13 such patients and 10 healthy male 46,XY normogonadic control subjects. Age and
body mass index were similar in the two groups. Nine of the 13 patients had hypergonadotropic
hypogonadism (five of whom had Klinefelter’s syndrome [karyotype 47,XXY]) and 4 of the 13 had
hypogonadotropic hypogonadism (46,XY). Of these last four, two had Kallmann’s syndrome and two
had idiopathic cryptorchidism.
Eight (61%) of the 13 patients studied had RADs unrelated to the etiology of their hypogonadism. Of
these, four had ankylosing spondylitis and histocompatibility B27 antigen, two had systemic lupus
erythematosus (in one case associated with antiphospholipids), one had juvenile rheumatoid arthritis,
and one had juvenile dermatomyositis. In comparison with the low frequencies of RADs in the general
population (about 0.83%, including systemic lupus erythematosus, 0.03%; dermatomyositis, 0.04%;
juvenile rheumatoid arthritis, 0.03%; ankylosing spondylitis, 0.01%; rheumatoid arthritis, 0.62%; and
other RAD, 0.1%), there were surprisingly high frequencies of such disorders in this small group of
patients with untreated hypogonadism (P < 0.001) and very low serum testosterone levels (P = 0.0005).
The presence of RADs in these patients was independent of the etiology of their hypogonadism and
was associated with marked gonadal failure with very low testosterone levels.
Keywords: ankylosing spondylitis, hypogonadism, rheumatic diseases, systemic lupus erythematosus, testosterone
Received: 10 January 2001
Revisions requested: 16 March 2001
Revisions received: 25 July 2001
Accepted: 7 August 2001
Published: 12 September 2001
Arthritis Res 2001, 3:362-367
This article may contain supplementary data which can only be found
online at http://arthritis-research.com/content/3/6/362
© 2001 Balderas et al, licensee BioMed Central Ltd
(Print ISSN 1465-9905; Online ISSN 1465-9913)
AS = ankylosing spondylitis; B27 = histocompatibility antigen B27; CREST = calcinosis, Raynaud's phenomenon, esophageal dysfunction, sclero-
dactyly, telangiectasia; E2 = estradiol-17β; JRA = juvenile rheumatoid arthritis; RA = rheumatoid arthritis; RAD = rheumatic/autoimmune disease;
SLE = systemic lupus erythematosus.
Available online http://arthritis-research.com/content/3/6/362Available online http://arthritis-research.com/content/3/6/362
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
r
e
s
e
a
r
c
h
 
a
r
t
i
c
l
e
Series of subjects with gonadal dysgenesis, and isolated
cases of Klinefelter’s syndrome associated with
rheumatic/autoimmune diseases (RAD), suggest a relation
between these clinical conditions [2,3]. Among male
patients reported to date who have hypogonadism and
RAD are individuals with systemic lupus erythematosus
(SLE) [4–7], lupus anticoagulant and antiphospholipid
syndrome associated [8], scleroderma [9–12], rheumatoid
arthritis (RA) [13], ankylosing spondylitis (AS) [14–16],
and polymyositis [17], while Turner’s syndrome has been
associated with autoimmune thyroiditis [3], juvenile
rheumatoid arthritis (JRA) [18], and juvenile-onset inflam-
matory bowel disease [19]. Only one of these reports
included eunuchoid males and female subjects with an
abnormal X karyotype [2].
Our goal in the present work was to determine whether
male patients with untreated hypogonadism have an
increased risk of developing RAD, and, if so, whether
there is a relation to the type of hypogonadism.
Methods
The clinical criteria of male hypogonadism refers to failure
of testicular function resulting in decreased production or
absence of male sex hormones and impaired spermatogen-
esis, whether this failure is secondary to hypothalamic and
pituitary dysfunction or is primary testicular failure [20].
From 60 patients who fulfilled the previous hypogonadism
criteria who were seen at the outpatient Andrology Clinic,
Mexico City, Mexico, from July 1998 to May 2000, 13 who
were not receiving hormone substitution were selected for
this study.
The clinical criteria of male ‘hypogonadism’ refers to failure
of testicular function resulting in decreased production or
absence of male sex hormones and impaired spermatogen-
esis, whether this failure is secondary to hypothalamic and
pituitary dysfunction or is primary testicular failure [20].
Ten normogonadic healthy male hospital staff with similar
age and body mass index [21] constituted the control
group for testicular size and hormone levels.
All the patients gave their informed consent. They and the
control subjects were given a neuroendocrine, genetic,
and clinic evaluation, including a physical exam, in addition
to computed tomography of the sella turcica and karyotyp-
ing of peripheral leukocytes. The presence of secondary
sexual characteristics and testicular volume (normal value
>20 ml) were noted.
In the patients, the rheumatolgic evaluation included a
search for the presence of diagnostic criteria for SLE,
RA, AS, psoriatic arthritis, JRA, polymyositis/dermato-
myositis, scleroderma/CREST (calcinosis, Raynaud’s
phenomenon, esophageal dysfunction, sclerodactyly,
telangiectasia), and Behçet’s syndrome [22]. Venous
blood (20 ml) was extracted to determine the erythrocyte
sedimentation rate (Wintrobe method, mm/h), lupus ery-
thematosus cells, rheumatoid factor (normal value
<20 IU/ml), antinuclear antibodies by immunofluores-
cence test (rat kidney substrate), anti-DNA (radioim-
munoassay), and Ro, La, Sm, and Scl-70 by
nephelometry to disclose autoimmune phenomena
and/or inflammatory serum subclinical abnormalities. The
histocompatibility antigen B27 (B27) was determined by
Terasaki’s joint-to-thyroid function test (Cis bio international
Groupe ORIS Cedex-France) using radioimmunoassay.
Serum levels of testosterone (double-antibody radio-
immunoassay technique), estradiol-17β (E2) (Interna-
tional CIS Sorin, Paris, France; double-antibody
radioimmunoassay kit), follicle-stimulating hormone,
luteinizing hormone, and prolactin (Diagnostic Products
Co, Los Angeles, CA, USA; double-antibody radio-
immunoassay kit) (in duplicate) were determined in
patients and controls. Coefficients of intra-assay and
interassay variations were, respectively, as follows:
testosterone, 6.0 and 10.4%; E2, 5.0 and 8.5%; follicle-
stimulating hormone, 3.1 and 7.7%; luteinizing hormone,
7.0 and 7.9%; and prolactin, 4.4 and 8.6%. X-rays were
made of the lumbosacral spine, sacroiliac joints, and
affected peripheral joints and were interpreted blind.
Affected tissues were biopsied as appropriate for the
clinical signs.
Fisher’s exact test and the Mann–Whitney U test were
used for statistical analysis (computer package Epi-Info,
Version 6.00; Centers for Disease Control and Prevention,
USA, World Health Organization, Geneva, Switzerland).
The significance limit was set at P < 0.05.
Results
Age and body mass index were similar in patients and
controls (mean ± standard deviation): respectively, age
25.3 ± 8.4 years vs 29.5 ± 7.6 years and body mass index
23.1 ± 3.3 kg/m2 vs 24.2 ± 3.6 kg/m2 (P = NS). The
testicular volume was 4.4 ± 4.3 ml in patients and
43.5 ± 3.5 ml in controls (P = 0.001). Nine of the 13
patients had hypergonadotropic hypergonadism, five of
whom had Klinefelter’s syndrome (47,XXY). The other four
of the 13 patients had hypogonadotropic hypogonadism
(46,XY); two of this group had Kallmann’s syndrome and
two had idiopathic cryptorchidism.
Eight out of the 13 male hypogonadic patients also had
RAD independently of the cause of their hypogonadism. Of
these, four had B27 + AS, two had SLE (in one case asso-
ciated with anti-phospholipid antibodies), one had JRA, and
one had juvenile dermatomyositis (Tables 1 and 2). We did
not find adult RA, scleroderma, scleroderma/CREST, psori-
atic arthritis, or Behçet’s syndrome.Arthritis Research    Vol 3 No 6 Jiménez-Balderas et al
Among the patients, age and body mass index were similar
in those with and those without RAD. Serum testosterone
and estradiol 17β levels were lower in those with RAD, but
only the difference in testosterone was highly significant
(1.0 ± 0.7 vs 2.7 ± 1.2 ng/ml, P = 0.0005) (see Supple-
mentary Table 1).
Discussion
As far as we know, this is the first report of an intentional
search for RAD in male patients with untreated hypogo-
nadism.
Usually, males with hypogonadism diagnosed in infancy or
in youth are those who have a complete hypogonadic clini-
cal picture. Some individuals, however, exhibit an incom-
plete clinical picture and may reach adulthood without
having their condition diagnosed. Their condition may
come to light during tests of sterility in a couple, or during
epidemiological studies [23–26], which have established
the frequency of male patients with hypogonadism.
At present, it is considered that the frequency of male
patients with hypogonadism in the general male popula-
tion is somewhere between 0.04 and 1% [23,24] and that
the most frequent genetic alteration found in these
persons is that causing Klinefelter’s syndrome, whose
prevalence is of the order of 0.02 to 0.09% in healthy
populations [23–26] and 0.2 to 41.3% in populations with
certain mental or behavioral problems [27–29].
Our study was performed in a smaller group of male
patients with hypogonadism to those that have been
reported previously, for two reasons. First, the patients
were studied in an andrology clinic for infertility and thus
are not an unselected sample of the general population.
Second, their hypogonadism had not been diagnosed or
treated previously. Although it is arguable that our series
of patients, not being a representative sample, is unsuit-
able for evaluation of the frequency of RAD in patients
with hypogonadism, we investigated RAD only in those
who had not been treated for their hypogonadism, to avoid
Table 1
Clinical, laboratory, and radiologic data for subgroup A: hypergonadotropic hypogonadal male patients with and without
rheumatic/autoimmune disease (RAD)
Patient Age Endocrine  and 
no. (years) genetic diagnosis Symptoms and disease duration Laboratory findingsa X-rays RAD
1 33 Klinefelter’s syndrome;  Mucocutaneous rash with  ANA +; anti-DNA, 100 IU/dl;  Normal SLE
47,XXY Raynaud’s phenomenon; 2 years LE cells +; ESR, 25 mm/h; 
B27 (–); GMN, IIB WHOb
2 18 Klinefelter’s syndrome;  Multiple venous thrombosis,  ANA +; anti-Ro +; La +;  Normal SLE 
47,XXY mucocutaneous rash, symmetrical  anti-DNA, 30 IU/dl; ESR, 32 mm/h;  and
polyarthritis; 6 weeks B27 (–); skin biopsy compatible with  APLS
SLE; serum antiphospholipid + IgG
3 20 Klinefelter’s syndrome;  Lumbar pain, morning stiffness,  ESR, 5 mm/h; B27 (+) Ankylosis  AS
47,XXY/sexual  Achilles tendinitis; 6 months;  of sacroiliac 
chromatin X(90%) Schober’s test, 4 cma joints
4 20 Testicular damage with  Symmetrical arthritis of knees;  ESR, 51 mm/h; LE cells +;  Normal JRA
hyperprolactinemia; 46,XY 15 years; Schober’s test, 6 cma B27 (–); synovial biopsy; 
rheumatoid arthritis
5 44 Bilateral orchidectomy  Chronic lumbar and hip pain, knee  ESR, 50 mm/h; B27 (+) Bilateral  AS
due to carcinoma of testicle;  arthritis, acute intermittent uveitis,  sacroiliitis
47,XY Achilles tendinitis; 6 years; 
Schober’s test, 4 cma
6 32 Klinefelter’s syndrome;  Asymptomatic ESR, 10mm/h; B27 (–) Normal None
47,XXY(68%)/46,XY(32%)
7 21 Gonadal dysgenesis with  Asymptomatic ESR, 15mm/h; B27 (–) Normal None
mosaicism; 45,X/47,XYY
8 17 Bilateral cryptorchidism,  Asymptomatic ESR, 15mm/h; B27 (–) Normal None
orchidectomy; 46,XY
9 31 True hermaphrodite; 46,XY Asymptomatic ESR, 41mm/h; B27 (–) Normal None
ANA = antinuclear antibodies; APLS = antiphospholipid syndrome; AS = ankylosing spondylitis; B27 = histocompatibility antigen B27; 
ESR = erythrocyte sedimentation rate; GMN = glomerulonephritis; JRA = juvenile rheumatoid arthritis; LE = lupus erythematosus; SLE = systemic
lupus erythematosus. aNormal values: anti-DNA, <20 IU/dl; ESR, <15 mm/h; Schober’s test, >5 cm. bWorld Health Organization [40].the possibility that androgen replacement had interfered
with the development of RAD [30,31].
Because the clinical picture of RAD in some of the
patients was severe, with clear systemic and articular
symptoms, their RAD had been diagnosed elsewhere.
However, other patients with hypogonadism who also had
JRA and AS had only a few articular symptoms, so slight
that the RAD had gone unnoticed until we looked for it.
Considering that the frequency of RAD in Mexico City,
where our study was performed, is about 0.83% (includ-
ing RA 0.62%; SLE 0.03%; polymyositis/dermatomyositis
0.04%; JRA 0.03%; AS 0.01%; and other RAD [Sjogren’s
syndrome, mix connective tissue disease, etc.], 0.1%)
[32], the relatively large number of cases of RAD in this
very small group of male patients with untreated hypogo-
nadism was surprisingly high (P < 0.001), suggesting a
strong relation between the two conditions (see Supple-
mentary Table 2). The development of RAD only in those
patients with severe testicular dysfunction suggests that
such dysfunction is one endogenous factor that predis-
poses to the development of RAD.
The disorder most frequent in our group was the combina-
tion of B27 with AS. The frequency of patients with B27
(all of whom also developed AS) was very high (30.7%),
leading to the conclusion that the risk that males with
hypogonadism will develop AS is higher than that of a
healthy Mexican mestizo (about 4%, P = 0.001) [33]. We
cannot explain this association at present.
The frequency of SLE in male patients with hypogonadism
was higher than would be expected in the general popula-
tion. Despite the increased odds ratio for the development
of SLE in such patients, the confidence interval was very
wide, suggesting that other factors in addition to hormonal
and genetic alterations affect the development of SLE in
these patients.
Our group of patients includes, as far as we know, the first
case of hypogonadism associated with juvenile dermato-
myositis. The development of dermatomyositis and JRA
was higher in our patients than in the general population
(P = 0.006 and P = 0.004, respectively; Supplementary
Table 2). Nevertheless, the confidence interval was not
calculable; therefore we conclude that these associations
are coincidental. The fact that frequency of  RA was no
higher in our group of patients than in the general popula-
tion suggests that the RA and hypogonadism are not
related, as has already been suggested [13].
Because the group of patients we studied was so hetero-
geneous (hypogonadism due to various causes, and
various RAD), we can conclude only that the hypogo-
nadism itself (regardless of its particular etiology) and the
very low serum testosterone levels are associated with the
increased frequency of RAD.
Studies in healthy, normogonadic males with RAD have
found low serum levels of testosterone and high levels of
E2 in patients with RA, SLE, and Sjögren’s syndrome
[34,35]. The inflamed tissues of normogonadic patients
Available online http://arthritis-research.com/content/3/6/362
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Table 2
Clinical, laboratory, and radiologic data for subgroup B: hypogonadotropic hypogonadal male patients, with and without
rheumatic/autoimmune disease (RAD)
Patient Age Endocrine  and 
no. (years) genetic diagnosis Symptoms and disease duration Laboratory findingsa X-rays RAD
1 23 Kallmann’s syndrome;  Intermittent lumbar and hip pain,  ESR, 3 mm/h; B27 (+) Bilateral  AS
46,XY  symmetrical ankle arthritis; 10 years;  sacroiliitis
Schober’s test, 4.5 cma
2 34 Kallmann’s syndrome;  Intermittent lumbar pain and morning  ESR, 7 mm/h; B27 (+) Ankylosis of AS
46,XY  stiffness; 10 years; Schober’s test, 4.5 cma sacroiliac joints
3 17 Idiopathic hypogonado- Photosensitive skin heliotrope rash,  ESR, 53 mm/h; CK, 182 U/ml;  Muscle  JDM
tropic MPHG; 46,XY;  alopecia, proximal muscle weakness with  C3, 115 mg/dl; C4, 76 mg/dl;  calcinosis
bilateral cryptorchidism atrophy, Gottron’s papules; 11 years;  ANA + speckled pattern; 
arthritis of MCP and PIP joints anti-DNA, 26 IU/ml; 
B27 (–); muscle biopsy: myositis
4 20 Idiopathic hypogonado- Asymptomatic ESR, 16 mm/h; B27 (–) Normal None
tropic MPHG with hyper-
prolactinemia; 46,XY; 
bilateral cryptorchidism; 
bilateral orchidectomy
ANA = antinuclear antibodies; AS = ankylosing spondylitis; B27 = histocompatibility antigen B27; CK = creatine kinase; ESR = erythrocyte
sedimentation rate; JDM = juvenile dermatomyositis; MCP = metacarpophalangeal; MPHG = male patient with hypogonadism; PIP = proximal
interphalangeal. aNormal values: anti-DNA, <20 IU/dl; C3, 80–120 mg/dl; C4,12–20 mg/dl; creatine kinase, 0–95 U/ml; ESR, <15 mm/h;
Schober’s test, >5 cm.with RAD contain intense cellular infiltrates rich in
macrophages. These cells have hormonal receptors
capable of converting testosterone and androstenedione
into estrone and E2 by means of aromatase [36–38]. An
increase in the activity of aromatase induced locally could
explain the drop in androgen levels and the increase in
estrogens observed in patients with RA [38]. However, in
our group of patients, serum testosterone and E2 were
both decreased. Therefore, in our hypogonadic male
patients, the main cause of the testosterone decrease was
not due to an increase in its conversion to E2 because the
gonadal failure caused a decrease of both hormones,
mainly of the testosterone, without showing an increment
from its conversion to E2. Although the effects of low
serum testosterone levels on the immune system have
been little studied, Bebo et al have shown that orchidec-
tomy in mice can diminish the flow of CD4+ activated in
experimental autoimmune encephalomyelitis [39]. In
humans, before treatment with androgens, patients who
have Klinefelter’s syndrome but not RAD have very dimin-
ished levels of testosterone associated with high levels of
IgG, IgA, IgM, IL-2, and IL-4 and with an absolute increase
of CD3+, CD4+, and the CD4+/CD8+ ratio [30]. In
patients who have both Klinefelter’s syndrome and RAD,
the diminished level of testosterone is associated with low
percentages of OKT3+ and OKT8+ and with an increase
of the OKT4/OKT8 ratio [31]. On the basis of our findings
and of the reports cited, we conclude that lack of testos-
terone increases humoral and cellular immunity. When
androgens are given, these abnormalities are reversed and
the clinical picture improves [30,31].
If our argument is correct, low serum testosterone levels
favor the development of RAD in the hypogonadic male
patient, while in the normogonadic male who develops RAD
(mainly in RA) the decrease of testosterone serum levels is
due to an increase in its metabolism for the activated
immune system, with the subsequent elevation of E2. These
differences could also explain the low or almost null associ-
ation of RA and hypogonadism [13]. In both cases, after
androgens are given, the clinical picture and the abnormali-
ties of the immune system are ameliorated [30,31,38].
In summary, males who have hypogonadism, regardless of
its cause, develop RAD more frequently than the general
population, when they have very low serum levels of
testosterone.
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Supplementary Table 1
Characteristics of male patients with hypogonadism with and without rheumatic/autoimmune disease (RAD)
Characteristic Patients with RAD (N = 8) Patients without RAD (N = 5) P a
Age (years) 27.5 ± 9.5 22.2 ± 6.2 NS
Body mass index 23.4 ± 2.1 23.8 ± 4.5 NS
Prolactin (ng/ml) 8.8 ± 7.1 18.6 ± 8.9 NS
Testosterone (ng/ml) 1.0 ± 0.7 2.7 ± 1.2 0.0005
Estradiol-17β (pg/ml) 10.2 ± 8.9 13.5 ± 18.0 NS
Estradiol-17β/testosterone 9.9 ± 10.3 4.8 ± 6.1 NS
Values for data are mean ± standard deviation. NS = not significant. aMann–Whitney U test.
Supplementary Table 2
Comparison of rheumatic/autoimmune diseases (RAD) and B27 frequency in male patients with hypogonadism (MPHG) and in
controls (general population in Mexico City)
Condition RAD/HGMP (%) RAD/controls (%) OR 95% CI P a
RAD/no RAD 8/5 (61) 368/43445b (0.83) 188.89 55.9–665.91 <0.001
Ankylosing spondylitis 4/9 (30.7) 5/43832b (0.01) 2697.4 531.6–13586.8 <0.001
Systemic lupus erythematosus 2/11 (15.3) 15/43822b (0.03) 449.5 0–2391.1 <0.001
Polymyositis/dermatomyositis 1/12 (7.6) 18/43837b (0.04) 187.2 – 0.006
Juvenile rheumatoid arthritis 1/12 (7.6) 14/43823b (0.03) – – 0.004
Rheumatoid arthritis 0/13 (0) 272/43565b (0.62) 0.0 0–63.7 0.9
Other RAD* 0/13 (0) 44/43793b (0.1) 0.0 0–407.1 0.9
B27 (+)/(–) 4/9 (30.7) 27/638c (4) 7.27 1.86–26.2 0.005
B27 = histocompatibility antigen B27; CI = confidence interval; OR = odds ratio; – = not calculable. aFisher exact test. bReference [32].
cReference [33]. *Other RAD = Sjögren’s syndrome, mix connective tissue disease, scleroderma, rheumatic fever, reactive arthritis etc.